モノクローナル抗体関連の提携とライセンス契約 (2016～2024年)

当レポートでは、モノクローナル抗体に関する昨今 (2016～2024年) の提携とライセンス契約の動向について分析し、全体的な取引件数の推移や、財務面 (支払条件) の傾向、主要企業 (全25社) による取引形成の動き、契約条件の傾向、技術別の詳細動向などを調査すると共に、近年の主要な提携取引の詳細情報を取りまとめてお届けいたします。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 モノクローナル抗体関連の取引形成の傾向

• イントロダクション
• モノクローナル抗体関連の取引の長期的動向
• モノクローナル抗体関連で最も活発な取引業者
• モノクローナル抗体関連の取引：取引の種類別
• モノクローナル抗体関連の取引：治療分野別
• モノクローナル抗体関連の取引：業界別
• モノクローナル抗体関連の取引：取引条件
  • モノクローナル抗体関連の取引：取引総額
  • モノクローナル抗体関連の取引：前払い金
  • モノクローナル抗体関連の取引：マイルストーン払い
  • モノクローナル抗体関連の取引：ロイヤルティ率

第3章 モノクローナル抗体関連の主な取引

• イントロダクション
• モノクローナル抗体関連の主要な取引：契約金額

第4章 モノクローナル抗体関連で最も活発な取引企業

• イントロダクション
• モノクローナル抗体関連の取引で最も活発な企業
• モノクローナル抗体関連の取引で最も活発な企業：プロファイル

第5章 モノクローナル抗体関連の契約締結の一覧

• イントロダクション
• モノクローナル抗体関連の契約締結の一覧

第6章 モノクローナル抗体関連の取引：技術の種類別

• 取引一覧
• 取引一覧：モノクローナル抗体関連、企業別 (ABC順)
• 取引一覧：モノクローナル抗体関連、取引の種類別
• 取引一覧：モノクローナル抗体関連、治療分野別
• 取引の種類の定義
• Biopharma Research Ltdについて
• 現在の提携
• 現在の契約
• Current Partnering刊行の最近のレポートタイトル

Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the monoclonal antibody deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of monoclonal antibody deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 974 monoclonal antibody deals announced since 2016 including financial terms where available including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of monoclonal antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2016.

Chapter 3 provides an overview of the leading monoclonal antibody deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of monoclonal antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific monoclonal antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in monoclonal antibody deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse monoclonal antibody collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Monoclonal Antibody Collaboration and Licensing Deals includes:

• Trends in monoclonal antibody dealmaking in the biopharma industry
• Directory of monoclonal antibody deal records covering pharmaceutical and biotechnology
• The leading monoclonal antibody deals by value
• Most active monoclonal antibody licensing dealmakers
• Monoclonal Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in monoclonal antibody dealmaking

• 2.1. Introduction
• 2.2. Monoclonal antibody deals over the years
• 2.3. Most active monoclonal antibody dealmakers
• 2.4. Monoclonal antibody deals by deal type
• 2.5. Monoclonal antibody deals by therapy area
• 2.6. Monoclonal antibody deals by industry sector
• 2.7. Deal terms for monoclonal antibody deals
  • 2.7.1 Monoclonal antibody deals headline values
  • 2.7.2 Monoclonal antibody deal upfront payments
  • 2.7.3 Monoclonal antibody deal milestone payments
  • 2.7.4 Monoclonal antibody royalty rates

Chapter 3 - Leading monoclonal antibody deals

• 3.1. Introduction
• 3.2. Top monoclonal antibody deals by value

Chapter 4 - Most active monoclonal antibody dealmakers

• 4.1. Introduction
• 4.2. Most active monoclonal antibody dealmakers
• 4.3. Most active monoclonal antibody deals company profiles

Chapter 5 - Monoclonal antibody contracts dealmaking directory

• 5.1. Introduction
• 5.2. Monoclonal antibody contracts dealmaking directory

Chapter 6 - Monoclonal antibody dealmaking by technology type

• Deal directory
• Deal directory - Monoclonal antibody deals by company A-Z
• Deal directory - Monoclonal antibody deals by deal type
• Deal directory - Monoclonal antibody deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Monoclonal antibody deals since 2016
• Figure 2: Active monoclonal antibody dealmaking activity - 2016 - 2024
• Figure 3: Monoclonal antibody deals by deal type since 2016
• Figure 4: Monoclonal antibody deals by therapy area since 2016
• Figure 5: Monoclonal antibody deals by industry sector since 2016
• Figure 6: Monoclonal antibody deals with a headline value
• Figure 7: Monoclonal antibody deals with an upfront value
• Figure 8: Monoclonal antibody deals with a milestone value
• Figure 9: Monoclonal antibody deals with a royalty rate value
• Figure 10: Top monoclonal antibody deals by value since 2016
• Figure 11: Most active monoclonal antibody dealmakers 2016 - 2024
• Figure 12: Monoclonal antibody deals by technology type since 2016